Factors influencing lopinavir and atazanavir plasma concentration. - Wikidata - wikimedia - TriplyDB

Factors influencing lopinavir and atazanavir plasma concentration.

Factors influencing lopinavir and atazanavir plasma concentration.

http://www.wikidata.org/entity/Q37476403

about

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Clinical pharmacokinetics of antiretroviral drugs in older persons.Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers

P2860

Q34309475-C8E92E51-FE18-47F2-9555-6D15F5FE0AA4 Q35079510-C0E4FD25-87BB-45E6-A942-DF1E0BA07FBA Q36905884-BBA08B13-C283-4AD9-A79F-9FE76255006D Q37712960-30C90717-CD32-4DE4-A2B6-13099A9BCCC7 Q39007008-2BAF7F71-25DF-4B12-817E-6883AD573150 Q57403878-2D58441F-2383-4C84-8257-AD97195F2BD4 Q58377826-AAAAA63B-CDE9-4028-AA55-BDD562C4E597

P2860

Factors influencing lopinavir and atazanavir plasma concentration.

http://www.wikidata.org/entity/Q37476403

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Factors influencing lopinavir and atazanavir plasma concentration.

@en

Factors influencing lopinavir and atazanavir plasma concentration.

@nl

type

label

Factors influencing lopinavir and atazanavir plasma concentration.

@en

Factors influencing lopinavir and atazanavir plasma concentration.

@nl

prefLabel

Factors influencing lopinavir and atazanavir plasma concentration.

@en

Factors influencing lopinavir and atazanavir plasma concentration.

@nl

P1433

Q37476403-777F741A-7380-4E58-B5B1-68EABE4D5D19

P1476

Q37476403-0809B1BF-431D-4372-9139-B6DDC22CF600

P2093

Q37476403-0DAEFE6B-8E0B-4DE1-B273-1E2718861167

Q37476403-11A17579-07E0-4CFB-BEBD-037F151A3778

Q37476403-34C733B0-04FE-4179-BD35-B864E0A48C50

Q37476403-47741662-5EC6-47E1-B1D1-0C02E9BE83D4

Q37476403-4D91EB07-3932-4DDE-BF7C-EE790EF8A5CE

Q37476403-6A7CC03B-286D-4B24-8B83-5C497679E567

Q37476403-798A9A72-6827-4FD5-B04E-59F30E37D514

Q37476403-7A0416F2-5A33-42B0-BB92-E59873CA30B1

Q37476403-946734FA-AB9D-425F-885F-BDD76356F7CE

Q37476403-CDB6E729-6693-4131-A0CB-96C5F592BF8F

P2860

Q37476403-0052E92D-E9AA-4EC0-A60B-A04B3EFA27FF

Q37476403-032E1EE8-07AA-4DAA-B9B5-076D157027A7

Q37476403-1D9FFD9A-1877-4088-A354-74E3FA2EBEE6

Q37476403-25A0BD47-CC11-48A9-B060-607C3821AB81

Q37476403-3D23988E-D98F-4E89-9D72-526228CA0D29

Q37476403-57416A5D-A76B-4C4B-BA64-6FF424AC38C2

Q37476403-5AF44AC4-1FD4-41D9-BA3A-B844A7A8E033

Q37476403-6224D643-EBD8-404D-9069-5821D434A596

Q37476403-63559C95-0CFC-4193-A2DA-8374E35C6910

Q37476403-70A5F062-E464-4A70-BB90-E6F71B39C877

P304

Q37476403-CBF088DD-999F-4679-B1A1-5176AEB8F68C

P31

Q37476403-35988C1A-8F05-4A41-8E68-FA58794025A8

P356

Q37476403-B801EAEF-435B-45D9-BFA3-CCC832B6BC91

P407

Q37476403-117D2A28-DF88-48AC-A3E0-B33B14E30181

P433

Q37476403-BB5AD4E7-5903-4B78-AB47-D2621DEC7B08

P478

Q37476403-7B299786-6E12-4533-99FF-772B2F63F1AC

P50

Q37476403-2F7830DC-09A6-4D6F-9221-5783247A09D9

Q37476403-45D81621-6A75-451D-953E-72592C187D58

Q37476403-A5118EEB-E829-4466-9CBB-E128C9783FEA

Q37476403-B687957C-EDD0-477B-AE68-45DDA5EA855C

Q37476403-E62838E4-C8FF-455C-9EA1-EE7C23DC30D0

P577

Q37476403-8AB2F9CA-8DBC-46DD-8AE3-33D895F0502F

P5875

Q37476403-52F98ED3-9ED6-4422-85A4-3A2BA13E39CC

P698

Q37476403-313AD0C5-2A0D-4194-ACE3-F9B51DF0C894

P932

Q37476403-0A251586-B11C-45CD-AC8D-93AC8FC796F6

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Factors influencing lopinavir and atazanavir plasma concentration.

@en

P2093

Alan Winston

http://www.w3.org/2001/XMLSchema#string

Brian Gazzard

http://www.w3.org/2001/XMLSchema#string

Clifford Leen

http://www.w3.org/2001/XMLSchema#string

David Back

http://www.w3.org/2001/XMLSchema#string

David Dunn

http://www.w3.org/2001/XMLSchema#string

Jonathan Ainsworth

http://www.w3.org/2001/XMLSchema#string

Loveleen Bansi

http://www.w3.org/2001/XMLSchema#string

Margaret Johnson

http://www.w3.org/2001/XMLSchema#string

Martin Fisher

http://www.w3.org/2001/XMLSchema#string

Philippa Easterbrook

http://www.w3.org/2001/XMLSchema#string

P2860

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Update on rifampin and rifabutin drug interactions.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients

Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.

Role of OATP transporters in the disposition of drugs.

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

P304

129-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKP408

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang Stöhr

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38074737

http://www.w3.org/2001/XMLSchema#string

P698

19897506

http://www.w3.org/2001/XMLSchema#string

P932

2793688

http://www.w3.org/2001/XMLSchema#string